(Q35734025)

10 August 2017

1 reference

title

Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome? (English)

1 reference

10 August 2017

1 reference

Viola Andresen

1

1 reference

10 August 2017

Stephan Hollerbach

series ordinal

2

1 reference

10 August 2017

publication date

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

27

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

283-292

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200427050-00001

10 August 2017

exact match

0 references

cites work

5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine

1 reference

12 December 2020

The pharmacological properties of the novel selective 5-HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat.

1 reference

12 December 2020

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

1 reference

12 December 2020

Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel

1 reference

12 December 2020

A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome

1 reference

12 December 2020

The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients

1 reference

12 December 2020

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

1 reference

12 December 2020

Alosetron for irritable bowel syndrome

1 reference

12 December 2020

Irritable bowel syndrome: new agents targeting serotonin receptor subtypes

1 reference

12 December 2020

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

1 reference

12 December 2020

FDA advisory panels recommend Lotronex be put back on market

1 reference

12 December 2020

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

1 reference

12 December 2020

Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.

1 reference

12 December 2020

Review article: clinical pharmacology of alosetron

1 reference

12 December 2020

Alosetron does not affect the visceral perception of gastric distension in healthy subjects

1 reference

12 December 2020

Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom.

1 reference

12 December 2020

Role of visceral afferent mechanisms in functional bowel disorders

1 reference

12 December 2020

Serotoninergic neuroenteric modulators

1 reference

12 December 2020

Alosetron: a case study in regulatory capture, or a victory for patients' rights?

1 reference

12 December 2020

Evidence that spinal 5-HT1, 5-HT2 and 5-HT3 receptor subtypes modulate responses to noxious colorectal distension in the rat

1 reference

12 December 2020

Serotonin: a mediator of the brain-gut connection

1 reference

12 December 2020

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients

1 reference

12 December 2020

Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome

1 reference

12 December 2020

New drugs in the management of the irritable bowel syndrome

1 reference

12 December 2020

Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients

1 reference

12 December 2020

FDA advisers warn of more deaths if drug is relaunched

1 reference

12 December 2020

Irritable bowel syndrome and the role of 5-HT. Proceedings of a roundtable meeting. New Orleans, Louisiana, USA. May 1998

1 reference

12 December 2020

Observations concerning the action of 5-hydroxytryptamine on the peristaltic reflex

1 reference

12 December 2020

FDA allows controversial bowel drug back on to market

1 reference

12 December 2020

5-HT3 receptors in the CNS: 3B or not 3B?

1 reference

12 December 2020

Role of loperamide and placebo in management of irritable bowel syndrome (IBS)

1 reference

12 December 2020

Serotonin and its implication for the management of irritable bowel syndrome.

1 reference

12 December 2020

Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron

1 reference

12 December 2020

Psychopharmacology of central serotonergic systems

1 reference

12 December 2020

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

1 reference

12 December 2020

Gender differences in regional brain response to visceral pressure in IBS patients

1 reference

12 December 2020

In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study

1 reference

12 December 2020

Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers

1 reference

12 December 2020

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome

1 reference

12 December 2020

1 reference

12 December 2020

10.2165/00002018-200427050-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

1044151280

0 references

1 reference